Effects of Simvastatin and Metformin on Inflammation and Insulin Resistance in Individuals with Mild Metabolic Syndrome
Authors: Bulcão, Caroline1; Fernando Flexa Ribeiro-Filho,1; Sañudo, Adriana2; Ferreira, Sandra G. Roberta3
Source: American Journal of Cardiovascular Drugs, Volume 7, Number 3, 2007 , pp. 219-224(6)
Publisher: Adis International
Abstract:
Background: In addition to lipid-lowering and insulin-sensitizing actions, statins (HMG-CoA reductase inhibitors) and metformin may have pleiotropic effects.Objective: To study the effect of simvastatin and metformin on insulin sensitivity and inflammatory markers.Methods: Forty-one subjects with body mass index (BMI) 25-39.9 kg/m2 and impaired glucose tolerance were randomized to receive simvastatin or metformin for 16 weeks. Blood samples were obtained for measurement of metabolic and inflammatory parameters before and after each treatment.Results: As expected, when compared with simvastatin, metformin therapy resulted in significant reductions in mean BMI, fasting plasma glucose, and homeostasis model assessment-insulin resistance (HOMA-IR), whereas simvastatin treatment resulted in significantly reduced total cholesterol, low-density lipoprotein-cholesterol (LDL-C), and apolipoprotein B levels. Independently of the medication used, significant decreases in C-reactive protein (CRP) and interleukin (IL)-6 were detected from baseline to treatment end. CRP showed a mean reduction of 0.12 ± 0.04 mg/dL (p = 0.002) over the 16-week intervention period and IL-6 a mean reduction was 0.35 ± 0.17 pg/mL (p = 0.046). No change was observed in the tumor necrosis factor-α levels. Baseline values of CRP and IL-6 and their percentage declines were correlated (r = 0.71 and r = 0.67, respectively; p < 0.001). In simvastatin recipients, no correlation was detected between reductions in CRP or IL-6 and lipids, whereas in metformin recipients, reductions in inflammatory markers were not correlated to BMI and HOMA-IR.Conclusion: Our findings suggest that both metformin and simvastatin have similar beneficial effects on low-grade inflammation, in addition to their classical effects on glucose and lipid metabolism. Moreover, they confirm the importance of treating at-risk individuals even before the precipitation of overt diabetes mellitus or full-blown metabolic syndrome.Keywords: Insulin resistance; Metabolic syndrome; Metformin; Metformin; Simvastatin; Simvastatin
Document Type: Research article
Affiliations: 1: 1 Division of Endocrinology, Department of Internal Medicine, Federal University of São Paulo, São Paulo, Brazil 2: 2 PGS Medical Statistics, São Paulo, Brazil 3: 3 Department of Nutrition, School of Public Health, University of São Paulo, São Paulo, Brazil

Click here for Page Help